ACP-204 er et eksperimentelt lægemiddel, der undersøges som en mulig behandling for psykose hos voksne med Alzheimers sygdom. Psykose kan omfatte symptomer som hallucinationer (at se eller høre ting, der ikke er der) og vrangforestillinger (falske overbevisninger). Dette lægemiddel testes for at se, om det kan hjælpe med at reducere disse forstyrrende symptomer hos patienter med Alzheimers sygdom. I dette studie sammenlignes ACP-204 med placebo (et inaktivt stof) for at bestemme, hvor effektivt lægemidlet er, og hvilken dosis der virker bedst.

Alzheimer’s Disease – Alzheimer’s disease is a progressive brain disorder that gradually destroys memory and thinking skills. The disease begins with mild memory loss and confusion, particularly with recent events and new information. As the condition advances, individuals experience increasing difficulty with language, problem-solving, and completing familiar tasks. The brain tissue progressively deteriorates due to the buildup of abnormal protein deposits called plaques and tangles. Over time, the disease affects judgment, behavior, and personality, leading to significant changes in how a person interacts with their environment. The progression typically occurs slowly over several years, with symptoms becoming more severe as more brain cells are damaged.

Psychosis – Psychosis is a mental health condition characterized by a disconnection from reality. People experiencing psychosis may have hallucinations, which involve seeing, hearing, or feeling things that are not actually present. They may also develop delusions, which are false beliefs that seem very real to the person but are not based in reality. The condition can cause disorganized thinking and speech, making it difficult to communicate clearly with others. Psychosis can develop gradually or appear suddenly, and symptoms may come and go in episodes. The severity and duration of symptoms can vary significantly between individuals.